Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

Host A2B Adenosine Receptors Promote Carcinoma Growth

(2015) Sergey Ryzhov et al.   NEOPLASIA

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Update on castrate-resistant prostate cancer: 2010

(2010) Kiran Lassi et al.   CURRENT OPINION IN ONCOLOGY

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

WT1 peptide immunotherapy for cancer in children and young adults

(2010) Yoshiko Hashii et al.   PEDIATRIC BLOOD & CANCER

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Adenosine A2a Receptor Inhibits Matrix-Induced Inflammation in a Novel Fashion

(2008) Kara A. Scheibner et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY